Diorasis Therapeutics, a Boston-based biotechnology company developing durable gene therapies for glaucoma and other ...

Olopatadine Hydrochloride Ophthalmic Solution is indicated for the treatment of ocular itching associated with allergic ...

RVL Pharmaceuticals, Inc. and its affiliates (together, "RVL") announces Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing ...

Multi-asset pipeline with significant targeted data readouts and milestones -- Two lead ophthalmic gene therapy programs in clinical trials ...

The approval is for its Abbreviated New Drug Application for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The product is therapeutically equivalent to Alcon Laboratories’ Pataday ...

Launched VIZZ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million in net pr ...

Gland Pharma jumped 4.80 per cent to ₹1,790.40, the highest level since December 3, 2025, on the National Stock Exchange.

Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in ...

OSN Cornea/External Disease Board Member Eric D. Donnenfeld, MD, and a panel of experts examined a series of unusual ...

A company claiming to be “America’s Largest Ophthalmic Pharmacy” has issued a recall for multiple eye drop products for the ...

FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...

Plastic packaging, accounting for 58.4% of market share, continues to outpace glass alternatives due to its lightweight, durable, and transparent properties. The material’s adaptability to complex ...